H.C. Wainwright raised the firm’s price target on Lenz Therapeutics (LENZ) to $56 from $48 and keeps a Buy rating on the shares after the FDA approved Vizz eye drops for the treatment of presbyopia in adults. Based on conversations with optometrists and ophthalmologists with prior experience prescribing AbbVie’s (ABBV) first-generation presbyopia eye drop Vuity, the firm believes physicians remain “optimistic and receptive” to Vizz, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LENZ:
- Buy Rating for LENZ Therapeutics: Vizz’s Early FDA Approval and Market Differentiation Drive Growth Potential
- Lenz Therapeutics price target raised to $52 from $49 at Citi
- LENZ Therapeutics Gains FDA Approval for VIZZ Eye Drop
- Lenz Therapeutics announces FDA approval of Vizz eye drop
- LENZ Therapeutics trading resumes